Rarely or never traded products pose a danger for naive investors stumbling about their choices.
Rarely or never traded products pose a danger for naive investors stumbling about their choices.
Parsing the performance and holdings of different biotech funds.
Misleading terms and confusing acronyms continue.
Sometimes an idea just gets you thinking about the possibilities.
There’s significant room for ETF growth within insurance companies.
Giving ETFs new names is a little like trying to make 'fetch' happen.
The ETF biz is a concentrated one, but there’s room to stand out among well-established giants.
The fund that tracks the Nasdaq-100 Index has marked a key milestone.